<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4346">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839042</url>
  </required_header>
  <id_info>
    <org_study_id>SC-Ad6-1-002</org_study_id>
    <nct_id>NCT04839042</nct_id>
  </id_info>
  <brief_title>A Phase 1, First-In-Human Study, to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetherex Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tetherex Pharmaceuticals Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose&#xD;
      study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1&#xD;
      investigational product when administered via intramuscular (IM) route in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with solicited local and systemic adverse events for 7 days Following Each Dose</measure>
    <time_frame>7 days following each dose</time_frame>
    <description>Solicited local adverse events are defined as pain, redness and swelling at the site of dose administration. Solicited systemic adverse events are defined as fever, headache, muscle pain, joint pain, fatigue, nausea or vomiting, and chills.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs), including withdrawals due to safety or tolerability reasons</measure>
    <time_frame>Up to 106 days following first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Humoral response to SARS-CoV-2 as measured by neutralizing antibodies using wild-type virus assay</measure>
    <time_frame>Up to 106 days following first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral response to SARS-CoV-2 as measured by serum IgG and IgA antibodies to the SARS-CoV-2 spike protein (ELISA)</measure>
    <time_frame>Up to 106 days following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral response to SARS-CoV-2 as measured by mucosal IgA antibodies to the SARS-CoV-2 spike protein (ELISA) and total mucosal IgA</measure>
    <time_frame>Up to 106 days following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of cytokine-producing T cells specific for the SARS-CoV-2 spike protein (ELISpot)</measure>
    <time_frame>Up to 106 days following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of adenovirus 6 (Ad6) neutralizing antibodies (anti-drug antibodies (ADA))</measure>
    <time_frame>Up to 106 days following first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>SC-Ad6-1 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose SC-Ad6-1, I.M., single-dose (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC-Ad6-1 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose SC-Ad6-1, I.M., single-dose (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC-Ad6-1 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose SC-Ad6-1, I.M., single-dose (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC-Ad6-1 Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Dose SC-Ad6-1, I.M., multiple-dose (Day 1 and Day 22)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SC-Ad6-1</intervention_name>
    <description>SC-Ad6-1, I.M., single or multiple-dose</description>
    <arm_group_label>SC-Ad6-1 High Dose</arm_group_label>
    <arm_group_label>SC-Ad6-1 Low Dose</arm_group_label>
    <arm_group_label>SC-Ad6-1 Medium Dose</arm_group_label>
    <arm_group_label>SC-Ad6-1 Multiple Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females, 18 to 55 years of age (inclusive)&#xD;
&#xD;
          -  Body mass index ≥ 18.0 and ≤ 32.0 kg/m2, with a body weight ≥ 50 kg at screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological&#xD;
             disease&#xD;
&#xD;
          -  History of chronic respiratory disorders including asthma, emphysema, interstitial&#xD;
             lung disease, pulmonary hypertension, recurrent pneumonia, or recent (≤14 days prior&#xD;
             to Screening) or ongoing respiratory tract infection&#xD;
&#xD;
          -  History of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, etc.), any&#xD;
             coagulation dysregulation disorder, or a history of thrombosis noted in immediate&#xD;
             family members&#xD;
&#xD;
          -  History of any neurological disorders or seizures including Guillain-Barre syndrome,&#xD;
             with the exception of febrile seizures during childhood&#xD;
&#xD;
          -  Known previous infection with SARS-CoV-2 or presence of antibodies against SARS-CoV-2&#xD;
             or a positive SARS-CoV-2 PCR test&#xD;
&#xD;
          -  Any history of malignant disease ≤5 years prior to registration&#xD;
&#xD;
          -  History of clinically relevant immunosuppression from, but not limited to,&#xD;
             immunodeficiency conditions such as common variable hypogammaglobulinemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Stocker, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tetherex Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Stocker, Ph.D.</last_name>
    <phone>855-222-0722</phone>
    <email>jstocker@tetherex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tetherex Study Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

